Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What do the statin trials tell us?

D D Waters1

  • 1Division of Cardiology, San Francisco General Hospital, University of California at San Francisco, 94110, USA. dwaters@medsfgh.ucsf.edu

Clinical Cardiology
|August 15, 2001
PubMed
Summary

Statins significantly reduce coronary events in patients with or without existing heart disease. This risk reduction improves over time and is linked to lower cholesterol levels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Action of nifedipine in ischemic heart disease.

Canadian family physician Medecin de famille canadien·2011
Same author

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.

Neurology·2010
Same author

Do statins confer early benefit after acute coronary syndromes? The results from FLORIDA.

European heart journal·2002
Same author

Short- and medium-term outcome differences in women and men after primary percutaneous transluminal mechanical revascularization for acute myocardial infarction.

The American journal of cardiology·2002
Same author

Comparison of electrocardiographic-gated technetium-99m sestamibi single-photon emission computed tomographic imaging and rest-redistribution thallium-201 in the prediction of myocardial viability.

The American journal of cardiology·2002
Same author

Low-density-lipoprotein cholesterol goals for patients with coronary disease: treating between the lines.

Circulation·2001

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Coronary heart disease (CHD) remains a leading cause of mortality worldwide.
  • Effective prevention strategies are crucial for managing cardiovascular risk.

Purpose of the Study:

  • To evaluate the benefits of statin therapy in preventing coronary events.
  • To analyze the efficacy of statins across different patient subgroups and risk factors.

Main Methods:

  • Analysis of five large-scale, randomized, placebo-controlled trials.
  • Inclusion of nearly 31,000 subjects in the meta-analysis.
  • Subgroup analyses examining efficacy in diverse populations.

Main Results:

  • Statins demonstrated a significant reduction in coronary event rates, irrespective of pre-existing CHD.
  • Risk reduction increased annually with statin use and was proportional to low-density lipoprotein cholesterol reduction.
  • Efficacy was confirmed in subgroups including women, diabetics, and the elderly.
  • Statins also reduced the risk of stroke and transient ischemic attacks.
  • Safety confirmed: no increased risk of cancer or mortality.

Conclusions:

  • Statins are safe and effective for managing hypercholesterolemia and preventing coronary events.
  • Long-term statin therapy offers progressive cardiovascular risk reduction.
  • Statins provide a robust foundation for future therapeutic advancements in cardiovascular disease management.

Related Experiment Videos